Study of LY2784544 Testing Alternative Dosing in Participants With Myeloproliferative Neoplasms

NCT01520220 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

100

Enrollment

INDUSTRY

Sponsor class

Conditions

Myeloproliferative Neoplasms of
Polycythemia Vera
Essential Thrombocythemia
Myelofibrosis

Interventions

DRUG: LY2784544

Sponsor

Eli Lilly and Company